China Pharma Holdings, Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2014. Unaudited consolidated results; the company manufactures and markets pharmaceutical products in China.
Financial performance
| Metric | Q3 2014 | Nine months 2014 | Comparable 2013 |
|---|---|---|---|
| Revenue | $5.57 million | $18.80 million | Q3 $8.12 million; nine months $24.39 million |
| Gross profit | $1.51 million | $6.59 million | Q3 $2.24 million; nine months $2.82 million |
| Gross margin | 27% | 35% | Q3 28%; nine months 12% (about 27% excluding 2013 inventory-obsolescence charges, per management) |
| Operating loss | $5.99 million | $16.86 million | Q3 $2.69 million; nine months $10.45 million |
| Net loss | $6.33 million | $17.36 million | Q3 $2.30 million; nine months $9.58 million |
| Loss per share, basic and diluted | $0.15 | $0.40 | Q3 $0.05; nine months $0.22 |
- Q3 revenue declined 31% year over year; nine-month revenue declined 23%. The company attributed much of the decline to suspension of its injectable production lines after missing the new GMP upgrade deadline.
- Nine-month bad-debt expense was $15.28 million, versus $7.91 million in 2013. The doubtful-account allowance rose to $27.91 million from $13.30 million at year-end 2013. Q3 bad-debt expense was $3.94 million.
- Cash from operations was $2.60 million for the nine months, down from $3.70 million. Investing cash outflow was $4.88 million; financing cash inflow was $0.60 million. Cash fell to $4.27 million from $5.99 million at December 31, 2013.
- At September 30, total assets were $140.53 million and total liabilities were $25.88 million. Current liabilities were $14.27 million and current assets $63.60 million.
- Debt included $4.88 million of short-term notes payable and $13.00 million of construction-loan borrowings, of which $1.63 million was current. The short-term bank loan was due November 1, 2014; the company was seeking an extension. The construction facility has an 8-year term and scheduled principal repayments begin July 2015.
Material changes and significant events
- The company recorded $2.28 million of typhoon-related losses in Q3, mainly inventory damage, after Typhoon Rammasun struck Haikou on July 18. Insurance compensation was approximately $0.01 million; management reported no required asset impairment or environmental remediation liability.
- In November 2014, after the quarter-end, the CFDA issued the GMP certificate for the new manufacturing facility. The company said it had commenced production on the liquid-injectable and dry-powder-injectable lines. It anticipated upgrading its existing sterilization facility the following year.
- Accounts receivable, net, declined to $30.64 million from $45.15 million at year-end, reflecting collection efforts and a larger allowance. The filing reports that 81.6% of receivables were aged over 360 days at September 30, including 43.2% over 720 days. Management offered two large customers a 30% discount for payment of outstanding balances, recording about $0.53 million in additional bad-debt expense.
- Customer concentration increased: one customer represented 16.7% of nine-month sales and 16.6% of receivables at September 30. One supplier represented 31.8% of nine-month raw-material purchases.
- One-time comparative factors affect margins: 2013 nine-month results included $3.74 million of inventory-obsolescence charges; 2014 included no such charge but did include the typhoon loss.
Outlook, liquidity, and risks
- Management believed operating cash flow would cover operating needs and anticipated capital spending over the next 12 months, but warned that a shortfall could require additional financing or spending reductions. No specific revenue or earnings guidance was provided.
- Management said pricing pressure was expected on most products, while newer products could support margins. It also described a prudent customer-credit strategy that limits credit sales and can weigh on revenue.
- Management reported that CFDA approval standards and timelines had lengthened, delaying the product pipeline. No new formulas received production approval during the first nine months of 2014; formula approvals commonly take about five years and can take longer. Approximately $5.19 million remained payable to laboratories and others as contract milestones are completed.
- All revenue is denominated in RMB. PRC controls on currency conversion and remittance, statutory reserve requirements, and the company’s indefinite-reinvestment position restrict access to cash at the U.S. parent. The $4.27 million cash balance was held at the PRC subsidiary and was not expected to be available for parent-company payments or dividends.
- Other disclosed risks include pharmaceutical price and policy changes, competition, reliance on government-backed hospital customers, aged receivables, and PRC political, legal, economic, and foreign-exchange conditions. The company reported no off-balance-sheet arrangements.
Key facts for investors to verify
- Whether the November GMP certification translated into sustained production, sales recovery, and acceptable utilization of the new lines.
- Whether the short-term loan due November 1 was extended or refinanced, and the terms and availability of any replacement liquidity.
- Collections after period-end, recoverability of the heavily aged receivables, and the adequacy of the $27.91 million allowance.
- The full effects of the typhoon on inventory, production, and facilities, including any additional insurance recoveries or costs.
- Progress and timing of CFDA formula approvals, milestone commitments, and the planned existing-facility upgrade.
- Whether the company can fund operations and capital needs despite declining revenue, operating losses, and limited access to PRC-held cash.